Technical Analysis for NXTC - NextCure, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.43 | -1.04% | -0.02 |
Earnings due: May 2
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 200 DMA | Bearish | -1.04% | |
| Wide Bands | Range Expansion | -1.04% | |
| Oversold Stochastic | Weakness | -1.04% | |
| Outside Day | Range Expansion | -6.86% | |
| Wide Bands | Range Expansion | -6.86% | |
| Oversold Stochastic | Weakness | -6.86% | |
| Wide Bands | Range Expansion | -11.49% | |
| Up 3 Days in a Row | Strength | -11.49% | |
| Oversold Stochastic | Weakness | -11.49% | |
| 50 DMA Resistance | Bearish | -10.94% |
| Alert | Time |
|---|---|
| 200 DMA Resistance | 28 minutes ago |
| Fell Below Previous Day's Low | about 1 hour ago |
| Down 2 % | about 1 hour ago |
| Down 1% | about 1 hour ago |
| Fell Below 200 DMA | about 20 hours ago |
Get a Trading Assistant
- Earnings date: 05/02/2024
NextCure, Inc. Description
NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Clinical Development Cancer Treatment Tumor Virotherapy Non Small Cell Lung Cancer Ovarian Cancer Small Cell Lung Cancer Oncolytics Biotech Metastasis Metastatic Solid Tumors Tumor Microenvironment Treatment Of Ovarian Cancer Halozyme Immune Related Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.57 |
| 52 Week Low | 0.98 |
| Average Volume | 334,115 |
| 200-Day Moving Average | 1.44 |
| 50-Day Moving Average | 1.72 |
| 20-Day Moving Average | 1.90 |
| 10-Day Moving Average | 1.64 |
| Average True Range | 0.20 |
| RSI (14) | 35.90 |
| ADX | 19.13 |
| +DI | 19.46 |
| -DI | 23.23 |
| Chandelier Exit (Long, 3 ATRs) | 1.98 |
| Chandelier Exit (Short, 3 ATRs) | 2.00 |
| Upper Bollinger Bands | 2.52 |
| Lower Bollinger Band | 1.27 |
| Percent B (%b) | 0.14 |
| BandWidth | 65.89 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.0675 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.79 | ||||
| Resistance 3 (R3) | 1.81 | 1.73 | 1.73 | ||
| Resistance 2 (R2) | 1.73 | 1.64 | 1.71 | 1.71 | |
| Resistance 1 (R1) | 1.58 | 1.58 | 1.54 | 1.56 | 1.69 |
| Pivot Point | 1.50 | 1.50 | 1.48 | 1.48 | 1.50 |
| Support 1 (S1) | 1.35 | 1.41 | 1.31 | 1.33 | 1.19 |
| Support 2 (S2) | 1.27 | 1.35 | 1.25 | 1.17 | |
| Support 3 (S3) | 1.12 | 1.27 | 1.15 | ||
| Support 4 (S4) | 1.10 |
